New chemo combo shows promise for tough breast cancer
NCT ID NCT01525966
First seen Apr 03, 2026 · Last updated Jun 20, 2026 · Updated 13 times
Summary
This phase II trial tests whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The study aims to increase the rate of complete remission (no cancer found at surgery) from 20% to 38%. About 67 participants are enrolled, and the approach may shrink tumors enough to allow less extensive surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope- South Pasadena Cancer Center
South Pasadena, California, 91030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carboplatin and nab-paclitaxel (chemotherapy drugs)
What this could lead to
If successful, this could show that giving these two chemotherapy drugs before surgery helps more patients achieve complete remission, potentially reducing the need for extensive surgery.
What could go wrong
This is a small, early-phase (Phase II) trial with only 67 participants. The results may not apply to all patients, and chemotherapy side effects can be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.